A Multicentric, Prospective, Randomized Study Evaluating the Improvement of Renal Function Outcomes With Dorzagliatin in Patients With Type 2 Diabetes Mellitus With Early Kidney Injury.

The main purpose of this study is to explore the improvement of renal function before and after the intervention of dorzagliatin in patients with type 2 diabetes.

Start Date20 Feb 2024

Sponsor / Collaborator

Nanjing Drum Tower Hospital

ChiCTR2400079946 / SuspendedPhase 4IIT

Predictive model of achieving glycemic target with Glucokinase agonist Dorzagliatin for type 2 diabetes:based on a real world study from China

Start Date31 Jan 2024

Sponsor / Collaborator-

NCT06263348 / RecruitingPhase 4

A Multicenter Post-Marketing Observational Study to Evaluate the Long-Term Safety of Dorzagliatin in Patients With Type 2 Diabetes Mellitus

The primary objective of this study is to evaluate the long-term safety of Dorzagliatin in a larger population of type 2 diabetes mellitus patients by collecting the post-marketing clinical safety data of Dorzagliatin.

Start Date20 Dec 2023

Sponsor / Collaborator

Hua Medicine (Shanghai) Co., Ltd.

[+1]

100 Clinical Results associated with Dorzagliatin

100 Translational Medicine associated with Dorzagliatin

100 Patents (Medical) associated with Dorzagliatin

Literatures (Medical) associated with Dorzagliatin

01 Oct 2024·MICROBIAL PATHOGENESIS

Identification of small molecule glucokinase activators for the treatment of diabetes based on plants from the traditional Chinese medicine: In silico analysis

Article

Author: Moussamih, Samya ; Douiyeh, Imane ; Safi, Amal ; Kettani, Anass ; Regragui, Anas ; Khamlich, Jihane ; Saih, Asmae

Mutations in glucokinase (GCK) can either enhance or inhibit insulin secretion, leading to different forms of diabetes, including gestational diabetes. While many glucokinase activators (GKAs) have been explored as treatments, their long-term effectiveness has often been unsatisfactory. However, recent interest has surged with the introduction of dorzagliatin and TTP399. This study investigates the efficacy of four previously studied compounds (Swertiamarin, Apigenin, Mangiferin, and Tatanan A) in activating GCK using computational methods. Initial molecular docking revealed binding affinities ranging from -6.7 to -8.6 kcal/mol. The compounds were then evaluated for drug-likeness and pharmacokinetic properties. Re-docking studies were performed for validation. Based on their favorable binding affinities and compliance with Lipinski's rule and ADMET criteria, three compounds (Swertiamarin, Apigenin, and Tatanan A) were selected for molecular dynamics (MD) simulations. MD simulations demonstrated that Swertiamarin showed excellent stability, as indicated by analyses of RMSD, RMSF, radius of gyration (Rg), hydrogen bonding, and principal component analysis (PCA). These results suggest that Swertiamarin holds promise for further investigation in in vivo and clinical settings to evaluate its potential in enhancing GCK activity and treating diabetes. This study assessed the potential of four compounds as GCK activators using molecular docking, pharmacokinetic profiling, and MD simulations. Swertiamarin, in particular, showed significant stability and adherence to drug-likeness criteria, making it a promising candidate for further research in combating diabetes.

30 Sep 2024·Anti-inflammatory & anti-allergy agents in medicinal chemistry

Molecular Docking, Pharmacophore Modeling, and ADMET Prediction of Novel Heterocyclic Leads as Glucokinase Activators

Article

Author: Mehra, Anuradha ; Singh, Shivangi ; Mittal, Amit

aims::

To address type 2 diabetes, as well as minimize unwanted side effects, this research endeavor aimed to develop activators of glucokinase.

background::

A pivotal impetus has driven the development of numerous small molecules aiming to improve therapeutic strategies for type 2 diabetes. Glucokinase (GK) activation has been offered a new realm of therapeutic antidiabetic activity with novel heterocyclic derivatives. In the context of antidiabetic drug design, GK is an interesting and newly validated target. A key enzyme needed for blood glucose homeostasis is Glucokinase, which is dysfunctional in individuals with type 2 diabetes. Heterocyclic derivatives are utilized in this innovative approach to activate GK enzymes as medicinal agents that will significantly improve type 2 diabetes management.

objective::

To address type 2 diabetes, as well as minimize unwanted side effects, this research endeavor aimed to develop activators of glucokinase.

method::

A rigorous scrutiny was conducted of the Maybridge online repository which houses a formidable collection of 53,000 lead compounds. A collection of 125 compounds that contain the thiazolidinedione core was selected from this extensive collection. The structures were generated using Chemdraw 2D, stabilize conformation with ChemBioDraw Ultra and docked using Auto Dock Vina 1.5.6 in this this methodology. In addition, log P was predicted online using the Swiss ADME algorithm. The PKCSM software was used to predict the toxicity of the leading compounds.

result::

The highest binding affinity was found for AS72 and AS108 to GK receptors. GI absorption and excretion of these compounds are efficient due to Lipinski Rule of Five compliance. When compared with the standard drugs Dorzagliatin (GKA) and MRK (co-crystallized ligand), these substances demonstrate a notable lack of AMES toxicity, skin sensitization, and hepatotoxicity.

conclusion::

In recent studies, lead molecules that possess enhanced pharmacokinetic profiles, increased binding affinity, and lower toxicity were developed to act as glucokinase activators.

other::

06 Aug 2024·CURRENT DRUG METABOLISM

Prediction of Protein-Drug Interactions, Pharmacophore Modeling, and Toxicokinetics of Novel Leads for Type 2 Diabetes Treatment

Article

Author: Mehra, Anuradha ; Vishwakarma, Prakhar Kumar ; Mittal, Amit

Background::

Small heterocyclic compounds have been crucial in pioneering advances in type 2 diabetes treatment. There has been a dramatic increase in the pharmacological development of novel heterocyclic derivatives aimed at stimulating the activation of Glucokinase (GK). A pharmaceutical intervention for diabetes is increasingly targeting GK as a legitimate target. Diabetes type 2 compromises Glucokinase's function, an enzyme vital for maintaining the balance of blood glucose levels. Medicinal substances strategically positioned to improve type 2 diabetes management are used to stimulate the GK enzyme using heterocyclic derivatives.

Objective::

The research endeavor aimed to craft novel compounds, drawing inspiration from the inherent coumarin nucleus found in nature. The goal was to evoke the activity of the glucokinase enzyme, offering a tailored approach to mitigate the undesired side effects typically associated with conventional therapies employed in the treatment of type 2 diabetes.

Methods::

Coumarin, sourced from nature's embrace, unfolds as a potent and naturally derived ally in the quest for innovative antidiabetic interventions. Coumarin was extracted from a variety of botanical origins, including Artemisia keiskeana, Mallotus resinosus, Jatropha integerrima, Ferula tingitana, Zanthoxylum schinifolium, Phebalium clavatum, and Mammea siamensis. This inclusive evaluation was conducted on Muybridge's digital database containing 53,000 hit compounds. The presence of the coumarin nucleus was found in 100 compounds, that were selected from this extensive repository. Utilizing Auto Dock Vina 1.5.6 and ChemBioDraw Ultra, structures generated through this process underwent docking analysis. Furthermore, these compounds were accurately predicted online log P using the Swiss ADME algorithm. A predictive analysis was conducted using PKCSM software on the primary compounds to assess potential toxicity.

Results::

Using Auto Dock Vina 1.5.6, 100 coumarin derivatives were assessed for docking. Glucokinase (GK) binding was significantly enhanced by most of these compounds. Based on superior binding characteristics compared with Dorzagliatin (standard GKA) and MRK (co-crystallized ligand), the top eight molecules were identified. After further evaluation through ADMET analysis of these eight promising candidates, it was confirmed that they met the Lipinski rule of five and their pharmacokinetic profile was enhanced. The highest binding affinity was demonstrated by APV16 at -10.6 kcal/mol. A comparison between the APV16, Dorzagliatin and MRK in terms of toxicity predictions using PKCSM indicated that the former exhibited less skin sensitization, AMES toxicity, and hepatotoxicity.

Conclusion::

Glucokinase is most potently activated by 100 of the compound leads in the database of 53,000 compounds that contain the coumarin nucleus. APV12, with its high binding affinity, favorable ADMET (adjusted drug metabolic equivalents), minimal toxicity, and favorable pharmacokinetic profile warrants consideration for progress to in vitro testing. Nevertheless, to uncover potential therapeutic implications, particularly in the context of type 2 diabetes, thorough investigations and in-vivo evaluations are necessary for benchmarking before therapeutic use, especially experiments involving the STZ diabetic rat model.

News (Medical) associated with Dorzagliatin

16 Feb 2023

·www.prnewswire.com

111, Inc. Hosts Hua Medicine Launches First Official Flagship Store

SHANGHAI, Feb. 16, 2023 /PRNewswire/ -- On February 15, 2023, 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company in China, announced that during the HuaTangNing® Market Launch for Innovative Commerce Cooperation, Dr. Yu Gang, Co-founder and Executive Chairman of 111, and Dr. Chen Li, Founder and CEO of Hua Medicine (HKEx stock code: 2552.HK), jointly unveiled the plaque of Hua Medicine's first official online flagship store on 111. 111 is committed to digitally connecting patients with medicine and healthcare services, aspiring to build itself into an integrated online and offline healthcare platform. The official flagship store launched by Hua Medicine on 111 will serve as an official window to showcase the outstanding brand image of Hua Medicine and an important platform for Hua Medicine to better serve both patients and doctors. For its part, 111 will further help Hua Medicine expand its commercial layout, broaden its drug supply and distribution channels, and explore innovative and diversified supply service modes. The official flagship store will provide patients with Hua Medicine's innovative treatment concepts, carry out patient education on drug safety and other topics, and release the latest news from Hua Medicine. Dr. Yu Gang, Co-founder and Executive Chairman of 111, said: "Hua Medicine is a leader in innovative drug research and commercialization in China. Over the years, it has devoted itself to the research and development of original drugs. HuaTangNing®, a first-in-class drug of its kind, is from Hua Medicine. The official opening of its flagship store on 111 is a timely and innovative measure taken by a Chinese innovative pharmaceutical company to embrace the Internet. At the same time, it also marks a key milestone for 111 and Hua Medicine in the exploration of online cooperation. 111 will work with Hua Medicine to make cutting-edge innovative drugs more accessible for diabetes patients, empower diabetes treatment as well as patient management, and contribute value to society." Dr. Li Chen, Founder and CEO of Hua Medicine, said: "111 is a benchmark player in China's Internet medicine and healthcare industry, equipped with leading digital technology and smart supply chain. We are very much looking forward to Hua Medicine's cooperation with 111, as we provide innovative solutions of health management and medical services through the online flagship store. In the future, Hua Medicine will continue to explore partnership opportunities with Internet channels to benefit more diabetic patients." About Hua Medicine Hua Medicine is an innovative drug development and commercialization company based in Shanghai, China, focused on developing novel therapies for patients worldwide with unmet medical needs. Based on global resources, Hua Medicine teams up with global high-caliber people to develop breakthrough technologies and products, which contribute a global innovation in diabetes care. As Hua Medicine's cornerstone product (dorzagliatin tablets), targeting the glucose sensor, glucokinase, restores glucose sensitivity in T2D patients and stabilizes the imbalance of blood glucose levels in patients, it has been approved by the National Medical Products Administration (NMPA) of China in September 2022. It can be used alone or in combination with metformin hydrochloride-tolerated T2D patients. For those patients with chronic kidney disease (CKD) and Type 2 diabetes (i.e., diabetes kidney disease), no dose adjustment is required. About 111, Inc. 111, Inc. (NASDAQ: YI) ("111" or the "Company") is a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China. The Company provides consumers with better access to pharmaceutical products and healthcare services directly through its online retail pharmacy, 1 Pharmacy, and indirectly through its offline virtual pharmacy network. The Company also offers online healthcare services through its internet hospital, 1 Clinic, which provides consumers with cost-effective and convenient online consultation, electronic prescription service, and patient management service. In addition, the Company's online platform, 1 Medicine, serves as a one-stop shop for pharmacies to source a vast selection of pharmaceutical products. With the largest virtual pharmacy network in China, 111 enables offline pharmacies to better serve their customers with cloud-based services. 111 also provides an omni-channel drug commercialization platform to its strategic partners, which includes services such as digital marketing, patient education, data analytics, and pricing monitoring. For more information on 111, please visit: . Forward-Looking Statements This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "target," "confident" and similar statements. Among other things, the Business Outlook and quotations from management in this announcement, as well as 111's strategic and operational plans, contain forward-looking statements. 111 may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Such statements are based upon management's current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's control. Forward-looking statements involve inherent risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. Potential risks and uncertainties include, but are not limited to, uncertainties as to the Company's ability comply with extensive and evolving regulatory requirements, its ability to compete effectively in the evolving PRC general health and wellness market, its ability to manage the growth of its business and expansion plans, its ability to achieve or maintain profitability in the future, its ability to control the risks associated with its pharmaceutical retail and wholesale businesses, and the Company's ability to meet the standards necessary to maintain listing of its ADSs on the Nasdaq Global Market, including its ability to cure any non-compliance with Nasdaq's continued listing criteria. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and 111 does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law. SOURCE 111, Inc.

27 Sep 2021

·www.biospace.com

Hua Medicine May be Sending Type 2 Diabetes into Remission

Is it a DREAM? On September 26, news emerged from Suzhou, China, that a glucokinase activator being developed by Chinese pharmaceutical company Hua Medicine may be heading toward making diabetes remission a reality. “DREAM” is a follow-up, observational clinical study of the Phase III SEED clinical study of dorzagliatin, a first-in-class glucokinase activator, which is being conducted in drug-naive Type 2 diabetes patients to determine its safety and efficacy. Its main objective is to determine if patients who participated in the SEED trial and achieved glycemic control as defined by investigators could maintain this for a minimum of 52 weeks without the intervention of any glucose-lowering medication. And many of them did. The analysis showed a 52-week glucose remission rate of 65.2% among the 69 patients being followed. Professor Jianhua Ma, director of the department of endocrinology at Nanjing First Hospital, standing member of the Chinese Diabetes Society and one of the principal investigators on the study, presented the findings at the 6th China BioMed Innovation and Investment Conference. “Dorzagliatin, a new class of glucokinase activator, has demonstrated the ability to effectively improve early phase insulin secretion and beta cell function and insulin resistance resulting in Type 2 diabetes remission,” Ma said, adding that dorzagliatin monotherapy had previously demonstrated stable long-term efficacy and a good safety pro the SEED study. “The DREAM study again showed positive results, where patients who reached normal blood glucose level after dorzagliatin treatment were able to maintain their blood glucose level and beta cell function after discontinuation of medication.” Ma went on to say that the study is of “great significance in expanding the treatment options for type 2 diabetes.” Hua Medicine is a clinical-stage drug development company based out of Shanghai, China, focussing on novel therapies for the treatment of diabetes and CNS disorders. According to Hua Medicine CEO, founder, and chief scientific officer Dr. Li Chen, China has the world’s largest number of diabetes patients, with the number of type 2 patients exceeding 120 million. He added that prevention and control of diabetes have become a “strategic imperative” in addressing this major public health issue. “The positive results of the DREAM study have strengthened our confidence in the cure of Type 2 diabetes,” Chen said. “Hua Medicine will continue to explore the broad prospects of monotherapy and combination therapy based on dorzagliatin, while further conducting typing studies and using a combination of big data and artificial intelligence for the precise treatment of Type 2 diabetes.” Per the Centers for Disease Control and Prevention (CDC), more than 34 million Americans have diabetes (around 1 in 10), with approximately 90-95% of the cases being Type 2. This is not the first time the idea of diabetes remission has been proposed. In 2020, Dr. Ebaa Al Ozairi, chief medical officer at the Dasman Diabetes Institute in Kuwait said that Type 2 diabetes remission with weight loss is possible and most likely for younger patients who sustain more weight loss and have had the disease for a shorter period of time. “We can no longer talk and tell our patients that diabetes is a chronic disease,” Ozairi, who is also an American Board of Physician Nutrition specialist, said during a presentation at ObesityWeek Interactive. “We have to give them the hope that we know today that diabetes remission is not a myth and is actually a reality. We really need to rethink treatment of Type 2 diabetes, so if it is treated early, we can achieve remission.” In 2018, Danish diabetes leader Novo Nordisk announced that it was upping its focus on stem cell therapy which replaces the beta cells missing in Type 1 diabetes patients with the aim of freeing patients from their dependence on insulin. In February, the company gave an update on its cell therapy efforts, saying that it expected to investigational new drug (IND) application toward the end of 2022, but that the initial indication would be in Parkinson’s disease, not diabetes. In January, Vertex Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) had approved an IND for its own cell therapy for Type 1 diabetes. Featured Jobs on BioSpace

First in ClassCell Therapy

26 Apr 2021

·www.biospace.com

Himalaya Therapeutics Announces Appointment of Brian Zhang as Chief Executive Officer

SAN DIEGO, April 26, 2021 /PRNewswire/ -- Himalaya Therapeutics ("Himalaya"), a clinical-stage biopharmaceutical company focused on development and commercialization in Greater China of a novel class of investigational antibody therapeutics for the treatment of solid tumor cancer, which are based on the Conditionally Active Biologics ("CAB") technology platform, today announced the appointment of Brian Zhang, Ph.D., as chief executive officer. "We are thrilled to welcome Dr. Zhang to our growing team. His extensive experience will help drive Himalaya towards its ambitious goals," said Carolyn Short, co-founder and president of Himalaya Therapeutics since its founding in 2014. "Dr. Zhang is our second executive hire this quarter as we ramp up, and will provide great leadership as we continue to build this world-class team." Dr. Zhang is a global pharmaceutical veteran, with decades of experience on the R&D side, overseeing products from discovery to commercialization, on the corporate side, leading and founding healthcare companies, and on the investing side, as a venture partner and an angel investor. While at Hoffmann-La Roche, he helped lead the development of Xenical and the discovery of Dorzagliatin, among others, and helped establish its bioinformatics group. More recently, he cofounded several biotechnology startups and invested in biopharmaceuticals. He received his Ph.D. from the UCLA School of Medicine and his B.S. from Nanjing University. He also conducted brain research at the Chinese Academy of Sciences, earning a grant for further study abroad. "I am excited to join the Himalaya team and look forward to taking the impressive pipeline of a dozen drug candidates to move into the Chinese market as well as globally. The CAB platform has the potential to be truly groundbreaking and applicable to some of the most challenging problems we have faced in our battle against cancer." About Himalaya Therapeutics Himalaya is a global clinical-stage biotechnology company with operations in San Diego, California, and Hong Kong, China. Himalaya is advancing its pipeline of novel monoclonal antibody and other protein therapeutic product candidates, which are designed to have more selective targeting, greater efficacy, and more cost-efficient and predictable manufacturing than traditional antibodies, through clinical trials. Its product candidates have been developed using CAB technology, which is protected by more than 500 issued and pending patents. Himalaya has two CAB programs currently in Phase 2 clinical testing in Hong Kong and Taiwan: BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). Himalaya has a co-development and collaboration agreement for an investigational CAB CTLA-4 antibody, BA3071, with BeiGene Ltd. for its development, manufacturing and commercialization in Greater China. Investor Contact: Nicholas Desjardins Himalaya Therapeutics ndesjardins@himalayatherapeutics.com

AntibodyADC

100 Deals associated with Dorzagliatin

External Link

KEGG	Wiki	ATC	Drug Bank
D11342	-	-	DB15123

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	CN	Hua Medicine (Shanghai) Co., Ltd.	30 Sep 2022

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glucose Intolerance	Phase 2	-	The Chinese University of Hong Kong	01 Aug 2022
Maturity-Onset Diabetes of the Young, Type 4	Phase 2	HK	The Chinese University of Hong Kong	30 Sep 2020
Diabetes Mellitus, Noninsulin-Dependent, 2	Phase 2	CN	Hua Medicine Ltd.	01 Sep 2015
Renal Insufficiency	Phase 1	CN	Hua Medicine (Shanghai) Co., Ltd.	25 Apr 2019
Diabetic Nephropathies	IND Application	CN	Hua Medicine (Shanghai) Co., Ltd.	-
Alzheimer Disease	Preclinical	CN	Hua Medicine (Shanghai) Co., Ltd.	13 Oct 2022
Diabetes Mellitus, Type 1	Preclinical	CN	Hua Medicine (Shanghai) Co., Ltd.	13 Oct 2022
Nonalcoholic Steatohepatitis	Preclinical	CN	Hua Medicine (Shanghai) Co., Ltd.	13 Oct 2022
Metabolic Syndrome	Preclinical	CN	Hua Medicine (Shanghai) Co., Ltd.	11 Dec 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ADA2022	Not Applicable	Mason-Type Diabetes	8	Dorzagliatin 75mg	sgdqxdpapv(xcmrrsqasx) = ovrjddklpw zkeetsrsxh (nhlhzeahly ) View more	-	01 Jun 2022
				Placebo	sgdqxdpapv(xcmrrsqasx) = dkgoqmffbx zkeetsrsxh (nhlhzeahly ) View more
DREAM (ADA2022)	Not Applicable	Diabetes Mellitus, Type 2	69	Dorzagliatin	rsdphdltdo(luymbnfcyp) = gbatgojyzs fvvyqtfnpo (rcvpkbhcqz, 53.4 - 77.0)	-	01 Jun 2022
NCT03141073 (DAWN, Pubmed \| Nat Med) Manual	Phase 3	Diabetes Mellitus, Type 2	767	metformin+Dorzagliatin	zfhjhdwltf(xfusiwrhsm) = jjprkjuwhy ofbkqjddtk (evrspttaqw, -1.11 to -0.93)	Positive	12 May 2022
				metformin+Placebo	zfhjhdwltf(xfusiwrhsm) = vibrmeegqm ofbkqjddtk (evrspttaqw, -0.45 to -0.26)
NCT03173391 (SEED, Pubmed) Manual	Phase 3	Diabetes Mellitus, Type 2	463	Dorzagliatin	quhhjtekvu(zvtqxqoeet) = bgtrfimcvd dnnoghmkaf (rjngjgjdoq, -1.19 to -0.95)	Positive	12 May 2022
				Placebo	quhhjtekvu(zvtqxqoeet) = zanuuubhid dnnoghmkaf (rjngjgjdoq, -0.68 to -0.32)
SEED (ADA2021)	Not Applicable	Diabetes Mellitus, Type 2	463	Dorzagliatin 75 mg	tyqwqrxorf(zyedqzheeb) = yitezmuwsm lkfzbdfqfa (agodaffskx ) View more	Positive	01 Jun 2021
				Placebo	sobhdruedi(fwyeyeehey) = fotykbwthq uoschnnfzd (lnpupdqdrx )
DAWN (ADA2021)	Not Applicable	Diabetes Mellitus, Type 2 Add-on	767	Dorzagliatin	vpfeialgaa(ngrpistwxz) = lekqqdaqtz xkifiskkis (kcqvepvwwy )	Positive	01 Jun 2021
				Placebo	vpfeialgaa(ngrpistwxz) = hltnzgflxz xkifiskkis (kcqvepvwwy )
NCT03173391 (HMM0301 \| SEED, NEWS) Manual	Phase 3	Diabetes Mellitus, Type 2	463	Dorzagliatin	ihygabkrix(mpxuwyijjf) = rwdmozcnpk boqkntzozy (yqskrbqljb ) View more	Positive	18 Jun 2020
				Placebo	ihygabkrix(mpxuwyijjf) = ibmljoaiiq boqkntzozy (yqskrbqljb ) View more
ADA2020	Not Applicable	Diabetes Mellitus, Type 2	463	Dorzagliatin 75 mg	tjavezuwjc(vrliedxiji) = idabtdjrdp uarkezxfgc (ncsxfpfsum ) View more	Positive	01 Jun 2020
				Placebo	eazlsgwwca(ppnhxjbond) = hcuqoixrlr osnxutjebm (owzspjsuii ) View more
NCT02561338 (CTgov)	Phase 2	Diabetes Mellitus, Noninsulin-Dependent, 2	258	HMS5552 (HMS5552 Dose 1)	lzcbqktkzs(rdctgibfyr) = obuqfopqif xmizunjikf (jdmmhvxnhi, vunezbooti - dbuirvxeel) View more	-	10 Mar 2020
				HMS5552 (HMS5552 Dose 2)	lzcbqktkzs(rdctgibfyr) = hhajvllfcl xmizunjikf (jdmmhvxnhi, wepbkqdqko - yjilgnryzt) View more
NCT02386982 (Pubmed) Manual	Phase 1	Diabetes Mellitus, Type 2	24	HMS5552 (75 mg twice daily)	golbxcieto(pftgdfvrsb) = rfkqzlfszy rvyshhuckg (lauivxwrct ) View more	Positive	01 Sep 2018
				HMS5552 (75 mg once daily)	golbxcieto(pftgdfvrsb) = rmmypdlnax rvyshhuckg (lauivxwrct ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis